Cancer patients exhibit significantly lower heart rate variability indices compared to age-matched controlsCancer is Linked to Reduced Heart Rate Variability

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer Published September 30, 2026 Study authors: Shih Hsiu-Hua, Chang Hsu-Chieh, Chen Po-Huang, Chang Chia-Lun, Chuang Yeu-Hui, Lai Jun-Hung, Gautama… PubMed ↗ DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that cancer patients show lower heart rate variability, but evidence is too low to use as a clinical biomarker.

This meta-analysis evaluated heart rate variability (HRV) indices in 3232 adults with physician-confirmed malignancy compared to age-matched non-cancer controls. The study focused on primary outcomes including SDNN, RMSSD, and pNN50, alongside secondary outcomes such as HF power and HRV-fatigue associations.

The analysis found significantly lower HRV in cancer patients across several metrics. Specifically, SDNN was lower by a mean difference of -14.05 ms (95% CI -18.20, -9.90; p < 0.001). RMSSD was also lower in cancer patients (MD -16.76 ms; 95% CI -21.23, -12.28; p < 0.001). The pNN50 index was reduced by -6.05% (95%lr 95% CI -9.36, -2.74; p < 0.001). In contrast, HF power did not show a statistically significant difference (p = 0.118).

The authors note that the evidence for all pooled outcomes is of very low certainty. Furthermore, the pooled estimates cannot determine if the observed HRV suppression is caused by the malignancy itself, cardiotoxicity, perioperative vagal withdrawal, or survivorship remodeling. Due to these limitations and the lack of standardized protocols, HRV is not currently an established clinical biomarker for cancer patients.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the physiological impact of malignancy on autonomic function. While previous coverage has explored non-pharmacological interventions like virtual reality to reduce anxiety in cancer patients, this finding provides data on autonomic dysfunction. The study confirms that cancer patients exhibit lower heart rate variability, though it does not specify if this is due to the disease or treatment-related factors.

Researchers looked at data from over 3,000 adults with confirmed cancer to see how the condition affects the heart. They specifically measured heart rate variability, which is a way to track how the heart responds to different signals. The study found that cancer patients had significantly lower scores in several heart rate measures compared to healthy people of the same age.

While the study shows a clear link between cancer and these lower heart rates, the evidence is not very strong. Because the data comes from many different sources, it is hard to say exactly why these numbers are lower. It could be caused by the cancer itself, the side effects of treatments, or other factors related to being ill.

Because of these uncertainties, heart rate variability is not currently used as a standard tool for doctors to monitor cancer patients. This study shows a link between the two conditions, but it does not provide a specific way to treat or manage the heart changes. Patients should talk to their doctors about what these findings mean for their specific situation.

What this means for you:

Cancer is linked to lower heart rate variability, but the evidence is currently too uncertain for clinical use.

Common questions

What is heart rate variability and why does it matter?

Heart rate variability measures how much the time between heartbeats changes. It shows how well the heart responds to different signals. This study found that cancer patients had lower scores in several heart rate measures, including SDNN, RMSSD, and pNN50, compared to healthy people.

Does this mean heart rate is a way to track cancer?

Not currently. While the study found a link between cancer and lower heart rate variability, the evidence is considered very low certainty. Because there are no standard ways to measure it yet, it is not used as a standard clinical tool for doctors to monitor cancer.

What caused the lower heart rates in the study?

The study could not determine the exact cause of the lower heart rates. It is unclear if the change was caused by the cancer itself, the side effects of medical treatments, or other factors related to the patients' health.

Study Details

Study typeMeta analysis

Sample sizen = 3,232

EvidenceLevel 1

PublishedSep 2026

PMID42809037

View Original Abstract ↓

BACKGROUND: Cancer-associated autonomic dysfunction may suppress heart rate variability (HRV), yet no meta-analysis has pooled between-group differences in established HRV indices across cancer types. This review quantified HRV differences versus non-cancer controls, HRV-fatigue associations, and longitudinal HRV trajectories. METHODS: PubMed, MEDLINE, CINAHL, Embase, and the Cochrane Library were searched through March 2026. Adults with physician-confirmed malignancy and ECG- or PPG-based HRV were eligible. Because time-domain indices scale with recording length, the DerSimonian-Laird random-effects pool was restricted a priori to short-term resting recordings (5-10 min) with age-matched non-cancer controls (Part A); long-term ambulatory recordings (12-30 h) were reported separately, and remaining studies synthesized narratively (Part B) or longitudinally (Part C). Certainty was assessed using GRADE (PROSPERO CRD42026130103). RESULTS: Twenty-eight studies (3232 participants; 9 cancer categories) were included; five met pooling criteria. Cancer patients showed lower SDNN (MD = -14.05 ms [95% CI -18.20, -9.90]), RMSSD (-16.76 ms [-21.23, -12.28]), and pNN50 (-6.05% [-9.36, -2.74]); all p < 0.001, I = 22.1-33.7%. HF power was non-significant (p = 0.118). Leave-one-out analyses confirmed robustness, and within-cancer studies consistently showed inverse HRV-fatigue correlations. All pooled outcomes were Very Low certainty. CONCLUSIONS: Cancer patients show consistently suppressed short-term time-domain HRV, a clinically plausible signal of autonomic impairment. Because it aggregates mechanistically distinct sources (malignancy, cardiotoxicity, perioperative vagal withdrawal, survivorship remodeling), the pooled estimate cannot attribute suppression to any cause, and Very Low certainty precludes recommending HRV as an established clinical biomarker. Treatment-phase-stratified studies with standardized protocols and non-linear indices are needed.

Cancer patients exhibit significantly lower heart rate variability indices compared to age-matched controlsCancer is Linked to Reduced Heart Rate Variability

How this fits prior evidence

Common questions

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Cancer patients exhibit significantly lower heart rate variability indices compared to age-matched controlsCancer is Linked to Reduced Heart Rate Variability

How this fits prior evidence

Common questions

More on Cancer

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties